Retatrutide Anesthesia and Perioperative Interaction: What Patients and Clinicians Need to Know

What Makes Retatrutide Different From Other GLP-1 Agents?

Retatrutide is not a standard GLP-1 receptor agonist. It activates three receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This triple mechanism, developed by Eli Lilly, produced 17.5% mean body-weight loss at 24 weeks in the Phase 2 dose-escalation trial (N=338) published in the New England Journal of Medicine [1]. No other approved or late-stage agent combines all three pathways.

That distinction matters for surgery. GLP-1 receptor activation slows gastric emptying through reduced antral contractility and delayed gastric transit [2]. Adding a glucagon component does not reverse this effect; glucagon at pharmacologic doses can actually suppress gut motility through separate pathways. The net result is that retatrutide carries at least the same gastric-emptying delay seen with semaglutide or tirzepatide, and possibly a greater one.

The Gastric Emptying Mechanism

GLP-1 receptor agonists reduce gastric emptying rate by 25 to 40 percent compared with placebo in scintigraphy studies [2]. Solid meals are affected more than liquids, and the effect persists even after weeks of therapy. A patient who has taken retatrutide within the past week may still have delayed motility on the day of surgery, regardless of when they last ate.

Why Triple-Receptor Activation Complicates Risk Modeling

Tirzepatide (dual GIP/GLP-1 agonist) already produces gastric-emptying delays that concern anesthesiologists. Retatrutide adds glucagon receptor agonism, which has independent effects on gastrointestinal motility. Because retatrutide has not yet received FDA approval and has no published gastric scintigraphy data specific to its three-receptor profile, clinicians must extrapolate from the GLP-1 and GIP literature [1][3]. That extrapolation should err toward caution.

Aspiration Risk Under General Anesthesia

Pulmonary aspiration of gastric contents is a rare but life-threatening complication. Its incidence under general anesthesia is estimated at 1 in 3,000 to 1 in 6,000 elective procedures, but the mortality rate from aspiration pneumonitis or pneumonia can reach 5 percent [4]. GLP-1 receptor agonists change the risk calculus by producing a stomach that may contain solid food hours after a standard nil-by-mouth fast.

Case reports published since 2022 describe patients on semaglutide presenting with residual gastric contents despite 8 to 12 hours of fasting [5]. The American Society of Anesthesiologists (ASA) issued an interim guidance statement in June 2023 acknowledging this concern directly.

What the ASA 2023 Interim Guidance Says

The ASA stated: "The Task Force on Preoperative Fasting acknowledges that patients on GLP-1 receptor agonists for weight management or diabetes may be at increased risk of regurgitation and pulmonary aspiration of gastric contents" [6]. The guidance recommended that, for elective procedures, patients on daily GLP-1 dosing hold the drug on the day of surgery. For weekly formulations, the ASA suggested considering holding the dose one week before surgery.

Retatrutide, once approved, is expected to be a weekly subcutaneous injection based on its Phase 2 dosing schedule [1]. That places it in the weekly-agent category under ASA framing, meaning a one-week hold before elective surgery is the conservative default.

Extended Fasting Protocols

Standard ASA fasting guidelines recommend 6 hours for solid food and 2 hours for clear liquids before general anesthesia [6]. Many anesthesiologists now extend solid-food fasting to 12 to 24 hours for patients on weekly GLP-1-class agents. Point-of-care gastric ultrasound, available at many academic centers, can confirm an empty antrum before induction [7]. A full antrum on ultrasound should prompt delay of elective cases.

Drug Interactions During the Perioperative Period

Insulin and Sulfonylureas

Retatrutide lowers blood glucose through multiple mechanisms: increased insulin secretion (GIP/GLP-1 pathway), reduced glucagon secretion (GLP-1 pathway), and appetite suppression leading to caloric restriction. When patients also take insulin or sulfonylureas, hypoglycemia risk rises substantially. Intraoperative hypoglycemia is dangerous and may be masked by anesthetic agents [8].

The American Diabetes Association Standards of Care recommend holding sulfonylureas on the day of surgery and reducing basal insulin doses by 20 to 50 percent in insulin-treated patients [8]. With retatrutide in the regimen, these reductions may need to be more aggressive. Blood glucose should be monitored every 30 to 60 minutes intraoperatively.

Opioids and Gastric Motility

Opioids independently slow gastric emptying through mu-receptor activation in the enteric nervous system [9]. Combining opioid premedication or intraoperative opioid analgesia with retatrutide creates additive delays in gastric transit. Anesthesiologists using opioid-sparing techniques, such as regional anesthesia or multimodal analgesia with acetaminophen and NSAIDs, reduce this compounding effect.

Antiemetics

Nausea is the most common adverse effect of retatrutide. In the Phase 2 trial, nausea occurred in up to 42 percent of patients in the highest-dose cohort [1]. Postoperative nausea and vomiting (PONV) is also common after general anesthesia. Patients on retatrutide carry a baseline nausea burden that raises their PONV score. Prophylactic dual-agent antiemetic therapy (ondansetron plus dexamethasone, for example) is reasonable for these patients following standard PONV risk stratification [10].

Glucocorticoids and Blood Glucose

Dexamethasone, commonly given as a PONV prophylactic, raises blood glucose for 6 to 12 hours after a single dose. In a patient on retatrutide who has also taken insulin, this transient hyperglycemia can cause post-dexamethasone glucose spikes followed by rebound hypoglycemia. Monitoring glucose for at least 6 hours postoperatively is appropriate when dexamethasone is used [8].

Recommended Perioperative Protocol for Retatrutide Patients

The framework below synthesizes ASA fasting guidance [6], ADA surgical standards [8], and published GLP-1 gastroparesis literature [2][5] into a stepwise plan. Because retatrutide is not yet FDA-approved, no retatrutide-specific label exists; this framework applies GLP-1-class principles with adjustments for its triple-receptor profile.

Preoperative Steps (7 to 14 Days Before Surgery)

1. Notify the anesthesiologist and surgeon that the patient is on retatrutide. Provide the dose and date of last injection.
2. For elective procedures, hold the most recent weekly dose so that at least 7 days have elapsed before the surgical date.
3. Review all concomitant glucose-lowering medications. Adjust insulin doses per ADA guidance [8]. Discontinue sulfonylureas 24 hours before surgery.
4. If the procedure cannot be delayed and a retatrutide dose was taken within 7 days, treat the patient as having a full stomach regardless of fasting duration.

Day-of-Surgery Steps

1. Confirm the patient has fasted from solids for at least 12 hours (extended from the standard 6 hours).
2. Clear liquids (water, clear broth, black coffee) are permitted until 2 hours before induction per standard ASA guidance [6], unless the anesthesiologist orders a stricter protocol.
3. Perform gastric ultrasound if available. A full antrum (antral cross-sectional area above 340 mm squared in the semi-recumbent position) suggests retained gastric contents and warrants rapid-sequence induction [7].
4. Use rapid-sequence induction (RSI) with cricoid pressure when there is any concern about delayed gastric emptying.
5. Continue glucose monitoring every 30 to 60 minutes intraoperatively [8].

Postoperative Steps

1. Resume retatrutide only after the patient is tolerating oral intake without significant nausea or vomiting.
2. Monitor blood glucose for at least 6 hours if dexamethasone was administered intraoperatively.
3. Resume co-administered insulin or oral agents only with meals, not prophylactically, until normal eating resumes.
4. Document the drug hold and resumption dates in the medication reconciliation record.

Can You Drink Alcohol on Retatrutide?

Alcohol use on retatrutide carries three distinct concerns. First, alcohol accelerates gastric emptying for liquids while simultaneously slowing solid-phase gastric transit, creating an unpredictable net effect on already-delayed gastric motility [11]. Second, alcohol and GLP-1 agonists both affect the reward pathways in the nucleus accumbens. Animal data and early human observational work suggest GLP-1 receptor activation reduces alcohol craving and consumption; clinical implications during active treatment are not yet fully characterized [12].

Third, and most practically, alcohol lowers blood glucose independently. In a patient taking retatrutide alongside insulin or a sulfonylurea, even moderate alcohol intake (two standard drinks) can produce clinically significant hypoglycemia, particularly in a fasted or calorie-restricted state [8].

Retatrutide's prescribing information (once finalized) will likely carry a general caution about alcohol, consistent with the class. Patients should discuss their specific alcohol use habits with their prescribing clinician. Moderate or heavy drinking during perioperative periods is inadvisable for entirely separate reasons related to wound healing, bleeding risk, and immune function [13].

Cardiovascular Medications and Anesthetic Drug Interactions

Many patients who qualify for retatrutide treatment carry comorbid cardiovascular disease or hypertension. Several relevant interactions exist at the anesthetic interface.

Beta-blockers blunt the tachycardic response to hypoglycemia, masking a key clinical warning sign. Patients on beta-blockers and retatrutide should have continuous intraoperative glucose monitoring rather than relying on heart-rate-based detection of hypoglycemia [8].

ACE inhibitors and ARBs increase hypotension risk during general anesthesia. The 2017 ACC/AHA Hypertension Guidelines, cited by the Society for Cardiovascular Anesthesiologists, recommend withholding ACE inhibitors and ARBs on the morning of surgery [14]. This is independent of but additive to any hemodynamic effects of GLP-1 agonism, which can produce modest reductions in systolic blood pressure.

Antiarrhythmic agents, particularly amiodarone and dronedarone, interact with volatile anesthetics to increase the risk of bradycardia and heart block. Retatrutide does not appear to directly affect cardiac conduction based on Phase 2 QTc data [1], but the combination of these agents should be noted in the anesthetic plan.

Special Populations: Obesity, Diabetes, and Bariatric History

Retatrutide is being developed for patients with obesity and type 2 diabetes, populations that already carry elevated surgical risk. Obesity independently increases aspiration risk through elevated intra-abdominal pressure, reduced lower esophageal sphincter tone, and higher rates of obstructive sleep apnea [4].

Patients with a history of bariatric surgery present an additional layer of complexity. Roux-en-Y gastric bypass changes gastric anatomy, alters GLP-1 secretion endogenously, and may modify drug absorption for subcutaneously injected peptides. No specific retatrutide data exist for post-bariatric patients; clinicians should consult with both the bariatric surgeon and endocrinologist before scheduling elective procedures.

Type 2 diabetes further complicates glycemic management perioperatively. The Society for Ambulatory Anesthesia recommends maintaining blood glucose between 140 and 180 mg/dL intraoperatively in most surgical patients [8]. Tight control below 110 mg/dL is associated with worse outcomes in surgical populations per the NICE-SUGAR trial (N=6,104), which found intensive glucose control increased 90-day mortality compared with conventional control (27.5% vs. 24.9%, P<0.001) [15].

Monitoring and Rescue Protocols

If aspiration occurs intraoperatively, immediate suctioning, bronchoscopy to clear airways, and lung-protective ventilation strategies are first-line responses [4]. There is no specific antidote for GLP-1-mediated gastroparesis; metoclopramide 10 mg IV may modestly accelerate gastric emptying and is sometimes used preoperatively in high-risk patients, though evidence specifically in GLP-1 agonist users is limited [2].

For intraoperative hypoglycemia (glucose <70 mg/dL), dextrose 25 g IV (50 mL of 50% dextrose) raises glucose by approximately 70 to 100 mg/dL in a 70 kg patient [8]. Recheck glucose 15 minutes after treatment. Glucagon 1 mg IM can be used if IV access is unavailable, but its efficacy may be reduced in patients fasted for extended periods due to depleted glycogen stores.